These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

259 related items for PubMed ID: 26823889

  • 21. Chromoplectic TPM3-ALK rearrangement in a patient with inflammatory myofibroblastic tumor who responded to ceritinib after progression on crizotinib.
    Mansfield AS, Murphy SJ, Harris FR, Robinson SI, Marks RS, Johnson SH, Smadbeck JB, Halling GC, Yi ES, Wigle D, Vasmatzis G, Jen J.
    Ann Oncol; 2016 Nov; 27(11):2111-2117. PubMed ID: 27742657
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Management of anaplastic lymphoma kinase positive orbito-conjunctival inflammatory myofibroblastic tumor with crizotinib.
    Kiratli H, Uzun S, Varan A, Akyüz C, Orhan D.
    J AAPOS; 2016 Jun; 20(3):260-3. PubMed ID: 27312965
    [Abstract] [Full Text] [Related]

  • 24. Presence of anaplastic lymphoma kinase translocation in sarcomatoid carcinoma of head and neck and treatment effect of crizotinib: A case series.
    Kim SM, Kim MJ, Jung HA, Sun JM, Choi YL, Ko YH, Park K, Baek CH, Son YI, Ahn MJ.
    Head Neck; 2015 May; 37(5):E66-9. PubMed ID: 25270523
    [Abstract] [Full Text] [Related]

  • 25. ALK oncoproteins in atypical inflammatory myofibroblastic tumours: novel RRBP1-ALK fusions in epithelioid inflammatory myofibroblastic sarcoma.
    Lee JC, Li CF, Huang HY, Zhu MJ, Mariño-Enríquez A, Lee CT, Ou WB, Hornick JL, Fletcher JA.
    J Pathol; 2017 Feb; 241(3):316-323. PubMed ID: 27874193
    [Abstract] [Full Text] [Related]

  • 26. First line crizotinib in anaplastic lymphoma kinase (ALK) rearranged squamous cell lung cancer.
    Mikes RE, Jordan F, Hutarew G, Studnicka M.
    Lung Cancer; 2015 Dec; 90(3):614-6. PubMed ID: 26519123
    [Abstract] [Full Text] [Related]

  • 27. ALK rearrangement in a large series of consecutive non-small cell lung cancers: comparison between a new immunohistochemical approach and fluorescence in situ hybridization for the screening of patients eligible for crizotinib treatment.
    Alì G, Proietti A, Pelliccioni S, Niccoli C, Lupi C, Sensi E, Giannini R, Borrelli N, Menghi M, Chella A, Ribechini A, Cappuzzo F, Melfi F, Lucchi M, Mussi A, Fontanini G.
    Arch Pathol Lab Med; 2014 Nov; 138(11):1449-58. PubMed ID: 24885803
    [Abstract] [Full Text] [Related]

  • 28. Effectiveness of Crizotinib for Inflammatory Myofibroblastic Tumor with ALK mutation.
    Ogata M, Hatachi Y, Ogata T, Satake H, Imai Y, Yasui H.
    Intern Med; 2019 Apr 01; 58(7):1029-1032. PubMed ID: 30449794
    [Abstract] [Full Text] [Related]

  • 29. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.
    Rodig SJ, Shapiro GI.
    Curr Opin Investig Drugs; 2010 Dec 01; 11(12):1477-90. PubMed ID: 21154129
    [Abstract] [Full Text] [Related]

  • 30. ALK inhibition for the treatment of refractory epithelioid inflammatory myofibroblastic sarcoma.
    Fujiya M, Kohgo Y.
    Intern Med; 2014 Dec 01; 53(19):2177-8. PubMed ID: 25274227
    [No Abstract] [Full Text] [Related]

  • 31. ALK-1 protein expression and ALK gene rearrangements aid in the diagnosis of inflammatory myofibroblastic tumors of the female genital tract.
    Fuehrer NE, Keeney GL, Ketterling RP, Knudson RA, Bell DA.
    Arch Pathol Lab Med; 2012 Jun 01; 136(6):623-6. PubMed ID: 22646268
    [Abstract] [Full Text] [Related]

  • 32. Epithelioid inflammatory myofibroblastic sarcoma of stomach: diagnostic pitfalls and clinical characteristics.
    Xu P, Shen P, Jin Y, Wang L, Wu W.
    Int J Clin Exp Pathol; 2019 Jun 01; 12(5):1738-1744. PubMed ID: 31933992
    [Abstract] [Full Text] [Related]

  • 33. Treatment-refractory ALK-positive inflammatory myofibroblastic tumour of the oral cavity.
    LaVigne AW, Meredith DM, D'Adamo DR, Margalit DN.
    BMJ Case Rep; 2018 Apr 11; 2018():. PubMed ID: 29643133
    [Abstract] [Full Text] [Related]

  • 34. Epithelioid Inflammatory Myofibroblastic Sarcoma of the Ovary With RANB2-ALK Fusion: Report of a Case.
    Fang H, Langstraat CL, Visscher DW, Folpe AL, Schoolmeester JK.
    Int J Gynecol Pathol; 2018 Sep 11; 37(5):468-472. PubMed ID: 28787324
    [Abstract] [Full Text] [Related]

  • 35. Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer.
    O'Bryant CL, Wenger SD, Kim M, Thompson LA.
    Ann Pharmacother; 2013 Feb 11; 47(2):189-97. PubMed ID: 23386065
    [Abstract] [Full Text] [Related]

  • 36. [Clinicopathological features of inflammatory myofibroblastic tumor].
    Zhu Y, Ding Y, Song GX, Li X, Ding R, Fan QH, Gong QX.
    Zhonghua Bing Li Xue Za Zhi; 2021 Mar 08; 50(3):194-200. PubMed ID: 33677881
    [Abstract] [Full Text] [Related]

  • 37. Targeting anaplastic lymphoma kinase in lung cancer.
    Shaw AT, Solomon B.
    Clin Cancer Res; 2011 Apr 15; 17(8):2081-6. PubMed ID: 21288922
    [Abstract] [Full Text] [Related]

  • 38. Multiplexed deep sequencing analysis of ALK kinase domain identifies resistance mutations in relapsed patients following crizotinib treatment.
    Huang D, Kim DW, Kotsakis A, Deng S, Lira P, Ho SN, Lee NV, Vizcarra P, Cao JQ, Christensen JG, Kim TM, Sun JM, Ahn JS, Ahn MJ, Park K, Mao M.
    Genomics; 2013 Sep 15; 102(3):157-62. PubMed ID: 23434628
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.